Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Giotrif

- PMLiVE

Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

The genetic blood disorder affects more than 800,000 people globally

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

Dupixent is now the first drug in the EU indicated for use in this patient population

- PMLiVE

AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 118,000 people globally

- PMLiVE

MHRA approves CStone Pharmaceuticals’ sugemalimab to treat lung cancer in adults

Approximately 49,200 people are diagnosed with lung cancer every year in the UK

- PMLiVE

Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

More than 5,000 patients in England are expected to be eligible for the anti-PD-1 therapy

- PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer

Just under 100 non-small cell lung cancer patients in England will be eligible for the drug

- PMLiVE

Jazz shares positive results for Zepzelca combination in phase 3 lung cancer study

Approximately 30,000 new cases of small cell lung cancer are reported in the US every year

- PMLiVE

Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension

Yuvanci is now the only single tablet combination therapy for PAH patients in Europe

- PMLiVE

Ipsen’s Kayfanda granted EC approval to treat cholestatic pruritus in Alagille syndrome

The rare genetic disorder affects approximately three in every 100,000 births globally

- PMLiVE

AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults

The rare liver disease affects approximately nine women for every one man

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links